Ventracor implants first European patient
24 May, 2005 by Renate KrelleSydney's Ventracor (ASX:VCR) has announced the first European implant of its VentrAssist device as part of its CE Mark Trial.
Genesis flush after ArboGen stoush settles
24 May, 2005 by Graeme O'NeillAuckland-based biotech Genesis Research (ASX/NZSX:GEN) has received a valuable boost to its bottom line after an out-of-court settlement of its long-running dispute with former US ally, Delaware-based forestry biotech company ArboGen.
Ambri back to the drawing board
24 May, 2005 by Ruth BeranMedical diagnostics company Ambri (ASX:ABI) is busy back at the drawing board developing a new chip biosensor after suspending the development of its SensiDX project.
Acrux signs dermatology products deal
23 May, 2005 by Ruth BeranSpecialty pharmaceutical company Acrux (ASX:ACR) has signed an agreement giving newly-formed San Francisco bay area company Napa Biosciences the rights to use Acrux's drug delivery technology in a number of dermatology products.
Ausbiotech appoints new CEO
19 May, 2005 by Staff WritersAustralian Red Cross Blood Service (ARCBS) executive Dr Anna Lavelle has been appointed as the new head of Australia's peak biotechnology industry organisation, AusBiotech.
Motivated by pharma woes, biotech blog makes debut
19 May, 2005 by Kevin DaviesA new life sciences blog, Biopeer, has made its debut at the 2005 Bio-IT World Conference and Expo.
In brief: Uscom, Antisense, Gropep, Bresagen
18 May, 2005 by Staff WritersSydney's Uscom (ASX:UCM) has responded to ASX's 'please explain' as to why its shares dropped from $1.40 on 10 May to a low of $1.00 on 17 May.
Epitan and pSivida complete sustained-release study
18 May, 2005 by Ruth BeranA proof of concept study by Melbourne's Epitan (ASX:EPT) and nanotechnology company pSivida (ASX:PSD) has found that pSivida's BioSilicon technology can be used in a liquid-based sustained-release formulation of Epitan's tanning drug Melanotan.
CSL opens new $33 million influenza vaccine centre
18 May, 2005 by Ruth BeranA new $33 million influenza vaccine centre has officially been opened at CSL premises in Parkville.
Progen encouraged by pilot trial results
17 May, 2005 by Graeme O'NeillA Phase IIa pilot trial of its promising PI-88 angiogenesis inhibitor in patients with advanced melanoma has convinced Brisbane cancer-drug developer Progen Industries (ASX: PGL, NASDAQ: PGLAF) to move its lead compound into a Phase IIb trial.
Eiffel looking to cut costs
16 May, 2005 by Ruth BeranDrug re-engineering company Eiffel (ASX:EIF) has issued shares worth a total of $70,000 as part of the cancellation of an employee contract, and is looking to cut costs.
Avastra trial delayed
16 May, 2005 by Ruth BeranThe clinical trial being run by Sydney biomaterials company Avastra (ASX:AVS) for its BioWeld device has been delayed by six months due to severe post-operative complications experienced by the first patient.
ARRM opts for voluntary receivership
16 May, 2005 by Staff WritersSources close to Adelaide-based Advanced Rapid Robotic Manufacturing have revealed that the company has gone into voluntary receivership.
Select Vaccines licenses hepatitis E antibodies
13 May, 2005 by Graeme O'NeillMelbourne's Select Vaccines (ASX:SLT) announced today it has licensed serologicals company Upstate USA to market and distribute Select's five proprietary monoclonal antibodies to hepatitis E virus for research purposes.
New tax relief could lure foreign biotech CEOs here
13 May, 2005 by Graeme O'NeillThis week's federal budget contained a taxation measure designed to prime a 'brain siphon' that could help Australian biotechnology companies recruit experienced CEOs and other experienced senior executives from the US, Britain and Europe.
